Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Rest of World organic sales grew 5.4% in the quarter, led by China, which delivered significant growth in implants |
| We achieved over 2% organic sales growth in 2023, above our projection driven by growth in three of our four segments |
| So Primescan Connect has actually seen some really good momentum |
| We've had very positive feedback from customers in Europe about it, and we do expect to bring that to the US market later this year as well |
| The SureSmile simulator is also expected to drive some better growth in the SureSmile business |
| On SureSmile, we continue to see market share gains, continue to see differentiated outcomes with our product with fewer refinements, less revisions of our product |
| And so that's why I'm confident that these investments are good investments, they're going to pay off in terms of faster revenue growth and why I'm talking at least 20% revenue growth on Byte in 2024 |
| We made significant progress on these initiatives, which have strengthened the foundation of the business and set us on a path to improved future performance, which we highlighted for you at our Investor Day in November |
| As we have said, we believe 2024 will be an inflection year for us, delivering double-digit adjusted EPS growth, largely due to the benefits of our transformation initiatives |
| That's seen a really nice sequential improvement from Q3 into Q4 |
| We are really excited about our ortho business |
| We've been super happy with China performance on implants this year |
| We've established the roadmap to reach our goals and are fully focused on execution, which we believe positions us well for improved performance in 2024 and beyond |
| Thirdly, we are building a durable, sustainable business that's better positioned to navigate external challenges and capitalize on new market opportunities as we move forward |
| We believe we are well positioned to advance digital print materials and continue to see opportunities to accelerate the adoption of 3D printing in dental practices, as a stand-alone office capability or as a complement to in-office milling |
| We expect that 2024 will be an inflection year for improved profitability and adjusted EPS growth |
| Fourth, we remain confident in the path to our targeted $3 of adjusted EPS in 2026 |
| Third, we are poised to deliver double-digit adjusted EPS growth in 2024, much of which we expect to derive from our transformational actions |
| Firstly, we are well positioned in attractive industries |
| We are significantly better positioned to deliver on our goals for the work that's been completed or is well underway |
| Obviously, a lot of that coming from China, but we also had really good performance in Europe |
| We demonstrated last year that we're able to drive net income performance on the Byte platform |
| The safety of our employees is of the utmost importance, and we are very proud of this accomplishment |
| And so the two together obviously drove a good result for us |
| The new system will unlock organizational capacity, enhance efficiencies in our network and pave the way for future automation opportunities company-wide |
| So, we feel good about improved performance in our U.S |
| And so we have seen some really good momentum post that decision |
| By streamlining our portfolio and utilizing a robust product life cycle management process, we can improve and simplify our supply chain and reduce sustaining engineering costs |
| Spearheaded by a dedicated and cross-functional team of experts, we expect this global initiative will yield significant results, including enhanced operational efficiency, improved footprint and lower costs |
| On a constant currency basis, the key highlights in the quarter included strong sales performance in China, which grew over 35%, double-digit growth in both Wellspect and Implants and Prosthetics and high single-digit growth in our global aligners business |
| Statement |
|---|
| Adjusted EPS in the quarter was $0.44, down 4% from the prior year, largely due to lower gross margins and a higher tax rate |
| The CTS segment declined slightly more than expected, mainly due to equipment and instruments with softness in imaging which we anticipate will continue in 2024 |
| I would just say that we did see some headwinds on the financing front in the fourth quarter with Bytes but only grew 6% in the fourth quarter, we had some financing constraints |
| German and Australian customers continue to express a negative outlook, and this is largely unchanged from the last quarter |
| The largest challenge we saw in 2023 was lower volumes in equipment and instruments, which we attribute to recessionary concerns and higher interest rates in the US, Germany and other developed markets as well as competitive pressure and we see this trend continuing into 2024 |
| Wrapping up our dental performance, CTS, our Connected Technology Solutions segment saw organic sales declined 8.3% versus the prior year quarter |
| We had indicated back in November that we expected lower growth in 2024 with a tough challenging macro environment |
| Despite higher sales, EBITDA margins declined 40 basis points in the quarter, mainly due to year-over-year decline in gross margins, which contracted 100 basis points |
| Through the fourth quarter, the macro environment remains challenging |
| EBITDA margins contracted 210 basis points to 17.4% due to cost inflation and higher investments in the commercial organization, clinical education and infrastructure, partially offset by restructuring benefits |
| I would assume that a lot of that R&D is going to general consumables, but we've been hearing more and more from public private dealers, from even some of your core manufacturing peers that there's been a lack of innovation on the consumables side for five, six, seven years now, and that's allowing some of these private label products or maybe lower price branded alternatives to come in and really put pressure on the higher-end branded consumable products out there |
| Foreign currency translation negatively impacted sales by 110 basis points due to a stronger dollar versus most major currencies |
| Our CTS segment continued to see lower volumes due to recessionary impacts, particularly in Germany, which is the largest market in the region |
| This was largely driven by unfavorable country mix due to lower-margin implant sales in China and unfavorable product mix within our endo and CAD/CAM portfolios |
| Operating cash flow was $377 million, down 27% year-over-year, driven by higher investments, restructuring cash outlays and unfavorable timing of accounts receivable and accounts payable |
| You talked about it with Byte, but I want to talk about it just in the context of -- right now, it's a difficult macro environment, our organic growth is 0% to 1.5% |
| But the equipment side of our business has been the big headwind for us |
| US sales declined 1.2% due to lower sales of equipment instruments and implants, partially offset by strong growth in aligners and CAD/CAM equipment |
| We expect FX to be a slight headwind to reported sales based on current rates and anticipate stronger organic sales growth in the second half of the year as we remain cautious on the macroeconomic backdrop for the next several quarters, particularly for equipment |
| Implant business, but it's still declining |
Please consider a small donation if you think this website provides you with relevant information